The use of different prognostic systems applied to myelodysplastic syndromes: A retrospective analysis

Advanced investigational methods in cytogenetics might improve the sensitivity of the IPSS and identify the heterogenous groups, especially in RA and RARS.

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:Sixty-nine patients with myelodysplastic syndromes (MDS) were followed at Dokuz Eylül University Medical School between 1990 and 1999 and have been reviewed retrospectively to compare the various prognostic systems.

📊

Temel Bulgular & Veri:All patients were scored according to the French-American-British (FAB) Cooperative Group and the Bournemouth Scoring System, and patients with available cytogenetic results (44 patients) were also scored according to the International Prognostic Scoring System (IPSS).

💡

Sonuç & Katkı:Advanced investigational methods in cytogenetics might improve the sensitivity of the IPSS and identify the heterogenous groups, especially in RA and RARS.

🔬Tür:Literatür & Derleme Çalışması

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Sağkalım oranı · Sitogenetik · Miyelodisplastik sendromlar

Özet

Sixty-nine patients with myelodysplastic syndromes (MDS) were followed at Dokuz Eylül University Medical School between 1990 and 1999 and have been reviewed retrospectively to compare the various prognostic systems. All patients were scored according to the French-American-British (FAB) Cooperative Group and the Bournemouth Scoring System, and patients with available cytogenetic results (44 patients) were also scored according to the International Prognostic Scoring System (IPSS). The median survival rate of patients was 33.6 ± 9.8 months. Both the Bournemouth and the IPSS groups correlated with the FAB subgroups in terms of median survival and 1 year survival rates. The estimated median overall survival rate (OS) was 43.7, 11.2 ± 3.0, 19.6 ± 10.5 months and 1 year OS was 88%, 43.5%, 55% for refractory anemia + refractory anemia with ring sideroblasts (RA+RARS), refractory anemia with excess of blasts+refractory anemia with excess of blasts in transformation (RAEB + RAEB-t) and CMML groups, respectively. Advanced investigational methods in cytogenetics might improve the sensitivity of the IPSS and identify the heterogenous groups, especially in RA and RARS.

Anahtar kelimeler

Sağkalım oranı Sitogenetik Miyelodisplastik sendromlar Geriyedönük çalışma Araştırma tasarımı Sitogenetik analiz

🔖

Bu Makaleye Atıf Yap

DEMİRKAN, F., ÇABUK, M., ÖZSAN, G. H., PEHLİVAN, M., YÜKSEL, E., ÖZTOP, İ., ÜNDAR, B. (2000). The use of different prognostic systems applied to myelodysplastic syndromes: A retrospective analysis. Turkish Journal of Hematology, Cilt: 17 - Sayı: 3, 101–109. https://ajindex.com/articles/412969

Kaynakça (12)

Koeffler HP. Myelodysplastic syndromes (preleuke mia). Semin Hematol 1986;23:284
Hofmann WK, Ottmann OG, Ganser A,Hoelzer D. Myelodysplastic syndromes: clinical features. Semin Hematol 1996;33:177-85
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndro mes. Br J Haematol 1982;51:189-99
Mufti GJ, Stevens JR, Oscier DG, et al. Myelodysp lastic Syndromes: A scoring system with prognostic significance. Br J Haematol 1985;59:425-33
Greenberg P, Cox C, LeBeau MM, et al. Internati onal scoring system for evaluating prognosis in mye lodysplastic syndromes. Blood 1997;89:2079-88. [Erratum, Blood 1998;91:1100.] 6. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British co operative group. Ann Intern Med 1985; 103:626-9
Nagai K, et al. Remission with morphological mye lodysplasia in de novo. acute myeloid leukemia: Imp lications for early relapse. Br J Haematol 1992; 81:33-9
ISCN (1991). Mitelman F (ed). Guidelines for Cancer Cytogenetics. Supplement to an International System for Human Cytogenetic Nomenclature. Kar ger: Basel 1991
Rosati S, Mick R, Xu F, et al. Refractory cytopenia with multilineage dysplasia: Further characterization of an "unclassifiable" myelodysplastic syndrome. Le ukemia 1996; 10:20-6
Tricot G, De Wolf-Peeters C, Van den Berghe H, Verwilghen RL. The myelodysplastic syndromes: Dif ferent evolution patterns based on sequential morp hological and cytogenetic investigations. Br J Ha ematol 1985;59:659-70
Seymour JF, Estey EH. The contribution of Auer Rods to the classification and prognosis of myelodysplastic syndromes. LeukLymphoma 1995; 17:79-85
Weimar IS, Bourhis JH, De Gast GC, Gerritsen WR. Clonality in myelodysplastic syndromes. Leuk Lymphoma 1994;13:215-21
Benitez J, Martinez FC, Toledo C, Fayos JS, Ramos C. Leukemic transformation in patients with the 5q- alteration: analysis of the behavior of the 5q- clones in preleukemic to leukemic phases. Cancer Genet Cytogenet 1987;26:199-207.